Oral Oncology
Volume 46, Issue 7 , Pages 519-524 , July 2010

Mutagen sensitivity and DNA repair of the EGFR gene in oropharyngeal cancer

Received 4 January 2010 ,Revised 12 March 2010 ,Accepted 12 March 2010.

References 

  1. Hunter KD, Parkinson EK, Harrison PR. Profiling early head and neck cancer. Nat Rev Cancer. 2005;5:127–135
  2. Matthias C, Bockmühl U, Jahnke V, Jones PW, Hayes JD, Alldersea J, et al. Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in upper aerodigestive tract cancers. Pharmacogenetics. 1998;8:91–100
  3. Grandis JR, Tweardy DJ. TGF-alpha and EGFR in head and neck cancer. J Cell Biochem Suppl. 1993;17:188–191
  4. Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol. 2009;21(2):177–184
  5. Hanawa M, Suzuki S, Dobashi Y, Yamane T, Kono K, Enomoto N, et al. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer. 2006;118(5):1173–1180
  6. Rubin Grandis J, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 1998;90(11):824–832
  7. van Oijen MG, Rijksen G, ten Broek FW, Slootweg PJ. Increased expression of epidermal growth factor receptor in normal epithelium adjacent to head and neck carcinomas independent of tobacco and alcohol abuse. Oral Dis. 1998;4(1):4–8
  8. Chung CH, Ely K, McGavran L, Varella-Garcia M, Parker J, Parker N, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol. 2006;24(25):4170–4176
  9. Hirsch FR, Varella-Garcia M, Bunn PAJ, Di Maria MV, Veve R, Bremmes RM, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003;21(20):3798–3807
  10. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol. 2006;24(17):2666–2672
  11. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–578
  12. Wild R, Fager K, Flefleh C, Kan D, Inigo I, Castaneda S, et al. Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels. Mol Cancer Ther. 2006;5:104–113
  13. Mrhalova M, Plzak J, Betka J, Kodet R. Epidermal growth factor receptor–its expression and copy numbers of EGFR gene in patients with head and neck squamous cell carcinomas. Neoplasma. 2005;52(4):338–343
  14. Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, et al. ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest. 2007;117(8):2051–2058
  15. McKelvey-Martin VJ, Melia N, Walsh IK, Johnston SR, Hughes CM, Lewis SE, et al. Two potential clinical applications of the alkaline single-cell gel electrophoresis assay: (1) human bladder washings and transitional cell carcinoma of the bladder; and (2) human sperm and male infertility. Mutat Res. 1997;375:93–104
  16. Hirsch FR, Varella-Garcia M, McCoy J, West H, Xavier AC, Gumerlock P, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a southwest oncology group study. J Clin Oncol. 2005;23(28):6838–6845
  17. Pugh TJ, Bebb G, Barclay L, Sutcliffe M, Fee J, Salski C, et al. Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients. BMC Cancer. 2007;7:128
  18. Burlinson B, Tice RR, Speit G, Agurell E, Brendler-Schwaab SY, Collins AR, et al. Fourth international workgroup on genotoxicity testing: results of the in vivo comet assay workgroup. Mutat Res. 2007;627:31–35
  19. Harreus UA, Kleinsasser NH, Zieger S, Wallner B, Reiter M, Schuller P, et al. Sensitivity to DNA-damage induction and chromosomal alterations in mucosa cells from patients with and without cancer of the oropharynx detected by a combination of comet assay and fluorescence in situ hybridization. Mutat Res. 2004;563(2):131–138
  20. Leprat F, Alapetite C, Rosselli F, Ridet A, Schlumberger M, Sarasin A, et al. Impaired DNA repair as assessed by the “comet” assay in patients with thyroid tumors after a history of radiation therapy: a preliminary study. Int J Radiat Oncol Biol Phys 1998;40(0360-3016) (Print):1019–26.
  21. Harreus U, Schmezer P, Kuchenmeister F, Maier H. Genotoxic effect on human mucous membrane biopsies of the upper aerodigestive tract. Laryngorhinootologie. 1999;78(4):176–181
  22. Luch A. The mode of action of organic carcinogens on cellular structures. EXS. 2006;96:65–95
  23. Liang Z, Lippman SM, Kawabe A, Shimada Y, Xu XC. Identification of benzo(a)pyrene diol epoxide-binding DNA fragments using DNA immunoprecipitation technique. Cancer Res. 2003;63(7):1470–1474
  24. Szekely G, Remenar E, Kasler M, Gundy S. Mutagen sensitivity of patients with cancer at different sites of the head and neck. Mutagenesis. 2005;20(5):381–385
  25. Glei M, Hovhannisyan G, Pool-Zobel BL. Use of Comet-FISH in the study of DNA damage and repair: review. Mutat Res. 2009;681(1):33–43
  26. Scully C, Field JK, Tanzawa H. Genetic aberrations in oral or head and neck squamous cell carcinoma (SCCHN): 1. Carcinogen metabolism, DNA repair and cell cycle control. Oral Oncol. 2000;36:256–263
  27. Ekwall K. Epigenetic control of centromere behavior. Annu Rev Genet. 2007;41:63–81
  28. Temam S, Kawaguchi H, El-Naggar AK, Jelinek J, Tang H, Liu DD, et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol. 2007;25(16):2164–2170
  29. Cappuzzo F, Varella-Garcia M, Shigematsu H, Domenichini I, Bartolini S, Ceresoli GL, et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol. 2005;23(22):5007–5018
  30. Freier K, Joos S, Flechtenmacher C, Devens F, Benner A, Bosch FX, et al. Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma. Cancer Res. 2003;63(6):1179–1182
  31. Koynova DK, Tsenova VS, Jankova RS, Gurov PB, Toncheva DI. Tissue microarray analysis of EGFR and HER2 oncogene copy number alterations in squamous cell carcinoma of the larynx. J Cancer Res Clin Oncol. 2005;131(3):199–203
  32. Zandi R, Larsen AB, Andersen P, Stockhausen MT, Poulsen HS. Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal. 2007;19(10):2013–2023
  33. McInerney JM, Wilson MA, Strand KJ, Chrysogelos SA. A strong intronic enhancer element of the EGFR gene is preferentially active in high EGFR expressing breast cancer cells. J Cell Biochem. 2001;80(4):538–549
  34. Amador ML, Oppenheimer D, Perea S, Maitra A, Cusatis G, Iacobuzio-Donahue C, et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res. 2004;64(24):9139–9143
  35. Buerger H, Packeisen J, Boecker A, Tidow N, Kersting C, Bielawski K, et al. Allelic length of a CA dinucleotide repeat in the EGFR gene correlates with the frequency of amplifications of this sequence–first results of an inter-ethnic breast cancer study. J Pathol. 2004;203(1):545–550

PII: S1368-8375(10)00110-7

doi: 10.1016/j.oraloncology.2010.03.019

Oral Oncology
Volume 46, Issue 7 , Pages 519-524 , July 2010

Article Tools

* Image Usage & Resolution